Abstract

Background

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third cause of cancer-related mortality world- wide. The incidence of HCC is on the increase, and it is a major threat to our modern life. Epidemiological studies have indicated that HCC are related to chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV) infection.

Aim of the Work

To detect prevalence, patterns, perioperative factors and outcome of recurrence of HCC after living donor liver transplantation.

Patients and Methods

This was a cross sectional study based on the review of medical records of all patients undergoing LT at Ain Shams Centre of Transplantation, between January 1, 2010, and December 31, 2018.

Results

we detected prevalence, patterns, perioperative factors and outcome of recurrence of HCC after living donor liver transplantation.

Conclusion

Oral lactoferrin could not be used as a substitute to totally replace IV ferrous sulphate in treating iron deficiency anemia in end stage renal disease (ESRD) on dialysis. Oral lactoferrin could not even control Hb level constant without dropping in patients with end stage renal disease (ESRD). Oral lactoferrin had some gastrointestinal effects on some patients which did not allow compliance on the medication.

This content is only available as a PDF.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://dbpia.nl.go.kr/pages/standard-publication-reuse-rights)
You do not currently have access to this article.